Low dose methotrexate impaired T cell transmigration through down-regulating CXCR4 expression in rheumatoid arthritis (RA).

ABSTRACT:

Background

CXC chemokine CXCL12 is involved in the pathological development of rheumatoid arthritis (RA) through abnormal migration of peripheral immune cells in the joint. Although low dose methotrexate (MTX) is clinically used to treat RA patients, CXCL12 signaling responses to MTX-mediated treatments is still not well understood.

Methods

In this study, we examined the expression of CXCR4 (cognatic receptor for CXCL12) in peripheral T cells from RA patients and arthritis mice models received from low dose MTX therapies. The effects of low dose MTX on CXCR4 were further determined via both in vitro CD3⁺ T cells and Cxcr4 conditional knockout (CKO) arthritis mice models.

Results

Our clinical data shows that low dose MTX treatment was clinically associated w

SUBMITTER: Ding L 

PROVIDER: S-EPMC11440717 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature